Federal Register / Vol. 72, No.
204 / Tuesday, October 23, 2007 / Notices
Document
7. .............................. Styrene (Update) ...........................................................................................................................................
* Denotes new profile.
All profiles issued as ‘‘Drafts for
Public Comment’’ represent ATSDR’s
best efforts to provide important
toxicological information on priority
hazardous substances. We are seeking
public comments and additional
information which may be used to
supplement these profiles. ATSDR
remains committed to providing a
public comment period for these
documents as a means to best serve
public health and our clients.
Dated: October 17, 2007.
Ken Rose,
Director, Office of Policy, Planning and
Evaluation, National Center for
Environmental Health/Agency for Toxic
Substances and Disease Registry.
[FR Doc. E7–20819 Filed 10–22–07; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration on Aging
Notice of Availability
Purpose of Notice: Availability of
funding opportunity announcement.
Funding Opportunity Title/Program
Name: Older Americans Act (OAA),
Title VI, Part A—Grants for Native
Americans, Part B—Grants for Native
Hawaiian Programs and Part C—Grants
for the Native American Caregiver
Support Program.
Announcement Type: This is the
initial announcement for this funding
opportunity.
Funding Opportunity Number:
Program Announcement No. HHS–
2008–AoA–Title VI–0802.
Statutory Authority: The Older
Americans Act, Public Law 109–365.
Catalog of Federal Domestic
Assistance (CFDA) Number: 93.047,
Title VI Parts A and B and 93.052, Title
VI Part C.
Dates: The deadline date for the
submission of applications is January
22, 2008.
I. Funding Opportunity Description
This announcement seeks proposals
for grants to provide nutritional and
rfrederick on PROD1PC67 with NOTICES
supportive services to Indian elders and
Native Hawaiian elders under Part A
and Part B and Family Caregiver
support services under Part C. The goal
of these programs is to increase home
and community based services to older
VerDate Aug<31>2005 15:33 Oct 22, 2007
60021
Hazardous substance
Indians, Alaska Natives and Native
Hawaiians, which respond to local
needs and are consistent with evidence-
based prevention practices. A detailed
description of the funding opportunity
may be found at http://
www.olderindians.org.
II. Award Information
1. Funding Instrument Type: Grant.
2. Anticipated Total Priority Area
Funding per Budget Period:
The Administration on Aging (AoA)
will accept applications for funding for
a three-year project period, April 1,
2008 to March 31, 2011, in FY 2008
under the OAA, Title VI, Part A—Grants
for Native Americans, Part B—Grants for
Native Hawaiian Programs and Part C—
Grants for the Native American
Caregiver Support Program. Current
annual funding levels for Title VI, Part
A and Part B range from $72,850 to
$135,500. Current annual funding levels
for Title VI, Part C range from $14,720
to $58,230. Distribution of funds among
tribal organizations and Native
Hawaiian organizations is subject to the
availability of appropriations to carry
out Title VI. Funding is based on the
number of eligible elders over the age of
60 in your proposed service area.
Successful applications from new
grantees will be funded pending
availability of additional funds. For
those applying for Title VI, Parts A and
B funding you have the option to also
apply for Part C. However, to apply for
Part C, you must apply for both Part A
and Part C or Part B and Part C.
III. Eligibility Criteria and Other
Requirements
1. Eligible Applicants
Eligibility for grant awards is limited
to all current Title VI, Part A and Part
B grantees, current grantees who wish to
leave a consortium, and eligible
federally recognized Indian tribal
organizations that are not now
participating in Title VI, and would like
to apply as a new grantee. Those Tribes
who were a part of a consortium
receiving a Title VI grant in 1991 and
applying individually will be
considered an ‘‘old grantee’’. Proof of
being a part of a consortium that was
funded in FY 1991 must be submitted
as part of the application. A tribal
organization or Indian tribe must meet
the application requirements contained
in sections 612(a), 612(b), and 612(c) of
Jkt 214001 PO 00000 Frm 00023 Fmt 4703 Sfmt 4703
CAS No.
000100–42–5
the OAA. A public or nonprofit
organization serving Native Hawaiians
must meet the application requirements
contained in sections 622(1), 622(2), and
625 of the OAA. Under the Native
American Caregiver Support Program, a
tribal or Native Hawaiian organization
must meet the requirements as
contained in section 631 of the OAA.
These sections are described in the
application kit.
2. Cost Sharing or Matching
Cost Sharing or matching does not
apply to these grants.
3. DUNS Number
All grant applicants must obtain a D-
U-N-S number from Dun and Bradstreet.
It is a nine-digit identification number,
which provides unique identifiers of
single business entities. The D-U-N-S
number is free and easy to obtain from
http://www.dnb.com/US/duns_update/.
4. Intergovernmental Review
Executive Order 12372,
Intergovernmental Review of Federal
Programs, is not applicable to these
grant applications.
IV. Application and Submission
Information
1. Address To Request Application
Package
Application kits are available by
writing to the U.S. Department of Health
and Human Services, Administration on
Aging, Office for American Indian,
Alaskan Native, and Native Hawaiian
Programs, Washington, DC 20201, by
calling 202/357–3537, or online at
http://www.olderindians.org.
2. Address for Application Submission
Applications must be sent overnight
delivery to the U.S. Department of
Health and Human Services,
Administration on Aging, Office of
Grants Management, 1 Massachusetts
Ave, NW., Room 4604, Washington, DC
20001, attn: Stephen Daniels (HHS–
2008–AoA–Title VI–0802). You must
submit one original and two copies of
the application.
3. Submission Dates and Times
To receive consideration, applications
must be received by the deadline listed
in the DATES section of this Notice.
E:\FR\FM\23OCN1.SGM 23OCN1
 60022 Federal Register / Vol. 72, No. 204 / Tuesday, October 23, 2007 / Notices
V. Responsiveness Criteria
Each application submitted will be
screened to determine whether it was
received by the closing date and time.
Applications received by the closing
date and time will be screened for
completeness and conformity with the
requirements outlined in Sections III
and IV of this Notice and the Program
Announcement. Only complete
applications that meet these
requirements will be considered for
funding.
VI. Application Review Information
Not Applicable.
VII. Agency Contacts
Direct inquiries regarding
programmatic issues to U.S. Department
of Health and Human Services,
Administration on Aging, Office for
American Indian, Alaskan Native and
Native Hawaiian Programs, Washington,
DC 20201, telephone: (202) 357–3501.
Dated: October 18, 2007.
Josefina G. Carbonell,
Assistant Secretary for Aging.
[FR Doc. E7–20837 Filed 10–22–07; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Joint Meeting of the Nonprescription
Drugs Advisory Committee and the
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees:
Nonprescription Drugs Advisory
Committee and the Endocrinologic and
Metabolic Drugs Advisory Committee.
General Function of the Committees:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 13, 2007, from 8 a.m.
to 5 p.m.
Location: Hilton Washington DC/
rfrederick on PROD1PC67 with NOTICES
Silver Spring, The Ballrooms, 8727
Colesville Rd., Silver Spring, MD. The
hotel telephone number is 301–589–
5200.
Contact Person: Diem-Kieu Ngo,
Center for Drug Evaluation and Research
VerDate Aug<31>2005 15:33 Oct 22, 2007 Jkt 214001
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
diem.ngo@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), codes
3014512541 and 3014512536. Please
call the Information Line for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
agency’s Web site and call the
appropriate advisory committee hot
line/phone line to learn about possible
modifications before coming to the
meeting.
Agenda: The committees will evaluate
data submitted by Merck & Co., Inc., to
support the over-the-counter use of
MEVACOR (lovastatin) 20 milligrams
(mg) a day to help lower cholesterol
which may prevent a first heart attack.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at http://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2007 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 29, 2007.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 15, 2007. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
PO 00000 Frm 00024 Fmt 4703 Sfmt 4703
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 16, 2007.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Diem-Kieu
Ngo at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
http://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 17, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7–20855 Filed 10–22–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held by teleconference on November 14,
2007, from 1 p.m. to approximately 4:30
p.m.
Location: National Institutes of
Health, Building 29B, Conference
Rooms A/B, Bethesda, MD. This
meeting will be held by teleconference.
The public is welcome to attend the
meeting at the specified location where
E:\FR\FM\23OCN1.SGM 23OCN1